Gilead Sciences


Gilead’s Yescarta Shows Significant Improvement in Survival in Follicular Lymphoma

Gilead Sciences’ (GILD) Kite Pharma reported follow-up data from the Zuma-5 trial of Yescarta in follicular lymphoma (FL). After a minimum period of …

Gilead’s Oral Epclusa Formulation Receives FDA Approval to Treat Hepatitis C in Children Aged 3 and Above

Gilead Sciences (GILD) has received approval from the U.S.

Gilead To Scale Up Remdesivir Availablity In India

Biopharmaceutical company Gilead Sciences is expanding the availability of its COVID-19 treatment Remdesivir in India amid the country’s spike in cases. Gilead (GILD) …

Gilead’s Bladder Cancer Drug Trodelvy Gets FDA Nod

Gilead Sciences’ Trodelvy (sacituzumab govitecan-hziy) has been granted accelerated approval by the US Food and Drug Administration (FDA) for use in the treatment …

Gilead, Novo Nordisk Expand NASH Collaboration

Gilead and Novo Nordisk are expanding their clinical collaboration for non-alcoholic steatohepatitis (NASH). Shares of Gilead, a biopharmaceutical company, are down about 1.

Gilead’s Kite Receives FDA Approval For Yescarta Immunotherapy; Street Sees 17% Upside

Kite, a unit of Gilead Sciences, announced that the US Food and Drug Administration (FDA) has approved its Yescarta T cell immunotherapy. The …

Gilead Revenues Increase 26% In Fourth Quarter Driven By Remdesivir Sales

Gilead Sciences posted fourth quarter and full year results yesterday that surpassed analysts’ expectations, largely driven by sales of its COVID-19 treatment, Remdesivir, …

Gilead Lifts 2020 Guidance Driven By Remdesivir Demand; Shares Gain

Gilead Sciences raised its full-year 2020 profit forecast on Monday fueled by demand for its remdesivir treatment during the COVID-19 pandemic. Shares rose …

Gilead Cuts 2020 Guidance As Remdesivir Sales Disappoint

Gilead Sciences lowered its 2020 guidance due to the global progression of the COVID-19 pandemic and uncertainty in forecasting sales of remdesivir, its …

Gilead’s Covid-19 Remdesivir Drug Scores FDA Approval; Shares Surge

Gilead Sciences (GILD) has announced that the U.S.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts